Literature DB >> 11893750

Physical interaction with human tumor-derived p53 mutants inhibits p63 activities.

Sabrina Strano1, Giulia Fontemaggi, Antonio Costanzo, Maria Giulia Rizzo, Olimpia Monti, Alessia Baccarini, Giannino Del Sal, Massimo Levrero, Ada Sacchi, Moshe Oren, Giovanni Blandino.   

Abstract

The p53 tumor suppressor gene is the most frequent target for genetic alterations in human cancers, whereas the recently discovered homologues p73 and p63 are rarely mutated. We and others have previously reported that human tumor-derived p53 mutants can engage in a physical association with different isoforms of p73, inhibiting their transcriptional activity. Here, we report that human tumor-derived p53 mutants can associate in vitro and in vivo with p63 through their respective core domains. We show that the interaction with mutant p53 impairs in vitro and in vivo sequence-specific DNA binding of p63 and consequently affects its transcriptional activity. We also report that in cells carrying endogenous mutant p53, such as T47D cells, p63 is unable to recruit some of its target gene promoters. Unlike wild-type p53, the binding to specific p53 mutants markedly counteracts p63-induced growth inhibition. This effect is, at least partially, mediated by the core domain of mutant p53. Thus, inactivation of p53 family members may contribute to the biological properties of specific p53 mutants in promoting tumorigenesis and in conferring selective survival advantage to cancer cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11893750     DOI: 10.1074/jbc.M201405200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  89 in total

1.  ΔNp63α regulates keratinocyte proliferation by controlling PTEN expression and localization.

Authors:  M K Leonard; R Kommagani; V Payal; L D Mayo; H N Shamma; M P Kadakia
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

2.  TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73.

Authors:  Kang Liu; Shiyun Ling; Weei-Chin Lin
Journal:  Mol Cell Biol       Date:  2011-09-19       Impact factor: 4.272

3.  Mutant p53 cooperates with ETS2 to promote etoposide resistance.

Authors:  Phi M Do; Lakshman Varanasi; Songqing Fan; Chunyang Li; Iwona Kubacka; Virginia Newman; Krishna Chauhan; Silvano Rakeem Daniels; Maurizio Boccetta; Michael R Garrett; Runzhao Li; Luis A Martinez
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

Review 4.  Therapeutic prospects for p73 and p63: rising from the shadow of p53.

Authors:  Anna Vilgelm; Wael El-Rifai; Alexander Zaika
Journal:  Drug Resist Updat       Date:  2008-09-17       Impact factor: 18.500

5.  Structural evolution of p53, p63, and p73: implication for heterotetramer formation.

Authors:  Andreas C Joerger; Sridharan Rajagopalan; Eviatar Natan; Dmitry B Veprintsev; Carol V Robinson; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-07       Impact factor: 11.205

6.  The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations.

Authors:  Matthew D Westfall; Deborah J Mays; Joseph C Sniezek; Jennifer A Pietenpol
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

7.  Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin.

Authors:  Kang Liu; Fang-Tsyr Lin; Joshua D Graves; Yu-Ju Lee; Weei-Chin Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

Review 8.  The p53 family and programmed cell death.

Authors:  E C Pietsch; S M Sykes; S B McMahon; M E Murphy
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

9.  Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family.

Authors:  Sebastian Kehrloesser; Christian Osterburg; Marcel Tuppi; Birgit Schäfer; Karen Heather Vousden; Volker Dötsch
Journal:  Cell Death Differ       Date:  2016-07-22       Impact factor: 15.828

10.  Mutant p53 mediates survival of breast cancer cells.

Authors:  L Y Lim; N Vidnovic; L W Ellisen; C-O Leong
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.